# Bioequivalence Test for Risperdal 2mg of Janssen Korea

> **NCT02012049** · PHASE1 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Risperdal OD Tab. 2mg
- **DRUG:** Risperdal Quicklet Tab. 2mg

## Key facts

- **NCT ID:** NCT02012049
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02012049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02012049, "Bioequivalence Test for Risperdal 2mg of Janssen Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02012049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*